Recruiting

Intermittent Fasting

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT07513116

Conditions

Evaluating

Intermittent Fasting

Pancreatic Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

intermittent fasting

Study Details

Brief summary:

To learn whether an eating pattern called intermittent fasting (IF) is tolerable and feasible for individuals at high risk of pancreatic cancer and whether IF is associated with changes in biological markers, including metabolic, inflammatory, microbiome, and imaging-related markers.

Conditions

Evaluating

Intermittent Fasting

Pancreatic Cancer

Study ID

NCT07513116

Start date

Jun 10, 2026

Status verified date

Oct, 2026

Completion date

Mar 30, 2029

Anticipated

Primary completion date

Mar 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria

  • Participants ≥ 18 years old. Participants under 18 are excluded due to their potential inability to understand and consent independently to the methods required for the study drug use and its potential risks and benefits.
  • Participants evaluated and classified as high risk for pancreatic cancer through a High-Risk Pancreatic Cancer Clinic or High-Risk Pancreatic Cyst Clinic, based on established clinical assessment and risk stratification.
  • High-risk status may include one or more of the following:

  • Hereditary cancer syndromes or known pathogenic germline mutations associated with pancreatic cancer risk
  • Family history of pancreatic ductal adenocarcinoma (PDAC)
  • Presence of pancreatic cysts or precursor lesions (e.g., IPMN, MCN)
  • New-onset diabetes mellitus is considered suspicious for pancreatic cancer
  • History of recurrent or chronic pancreatitis
  • Eligibility and surveillance risk assessment must be consistent with NCCN (National Comprehensive Cancer Network) Guidelines for Pancreatic Cancer Screening in High- Risk Individuals.
  • Participants are able to understand and are willing to sign a written informed consent document.
  • Both English-speaking and non-English-speaking participants are eligible for participation
  • Participants are willing to make a change in eating time patterns.
  • Participants are willing to provide App-tracked fasting time data over the course of the study.

Exclusion Criteria

  • BMI < 18.5 Kg/m2
  • Documented history of symptomatic hypoglycemia
  • Pregnant or breastfeeding women
  • Cognitively impaired individuals

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: Intermittent fasting

Fast for 16 consecutive hours each day and have an 8-hour window for eating.

Interventions

intermittent fasting

They will fast for 16 consecutive hours each day and have an 8-hour window for eating.

Primary outcome measure

  • Safety and adverse events (AEs). [ Time Frame: Through study completion; an average of 1 year. ]

Central Contacts and Locations

Central contacts

Florencia McAllister, MD

713-745-0914fmcallister@mdanderson.org

Locations

MD Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Florencia McAllister, MD

713-745-0914fmcallister@mdanderson.org

Principal Investigator:

Florencia McAllister, MD

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Oct 14, 2026

Last verified

Oct, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-15. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-10-14. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.